Status
Conditions
Treatments
About
In this study, patients with dysfunction of the eustachian tube will be included. They will be randomized to one of two treatment groups.
Full description
Patients will eustachian tube dysfunction will be asked to participate in the study.
They will be randomized to one of two groups
group 1 - surgical dilation of the eustachian tube in general anaesthesia
group 2 - daily nasal saline spray, twice a day
Regular Follow up with Tympanogram and Questionnaire
After three months patient in the control group (nasal saline) can switch in the intervention group.
Eustachian tube dilation will be carried out with a Health Canada and FDA approved device, usually used for endovascular balloon dilation. It has the same size and pressure properties as the eustachian tube dilation device and has shown a good safety profile in a previous preclinical and clinical pilot study.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Diagnosis (both required):
i. Persistent OETD symptoms assessed by Eustachian Tube Dysfunction Questionnaire (ETDQ-7) with overall score of ≥3 (moderate to severe symptoms) for 3 months or more prior to enrollment.
ii. Refractory to medical therapy (minimum of 4 weeks of daily intranasal steroid spray or one completed course of an oral steroid within 3 months before study enrollment).
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
15 participants in 2 patient groups
Loading...
Central trial contact
Kaye Dizon
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal